Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action by Ponnusamy, Suriyan et al.
ONCOLOGY REPORTS  35:  2097-2106,  2016
Abstract. Colon and pancreatic cancers contribute to 90,000 
deaths each year in the USA. These cancers lack targeted 
therapeutics due to heterogeneity of the disease and multiple 
causative factors. One important factor that contributes 
to increased colon and pancreatic cancer risk is gastrin. 
Gastrin mediates its actions through two G-protein coupled 
receptors (GPCRs): cholecystokinin receptor A (CCK-A) 
and CCK-B/gastrin receptor. Previous studies have indicated 
that colon cancer predominantly expresses CCK-A and 
responds to CCK-A isoform antagonists. However, many 
CCK-A antagonists have failed in the clinic due to poor 
pharmacokinetic properties or lack of efficacy. In the present 
study, we synthesized a library of CCK-A isoform-selective 
antagonists and tested them in various colon and pancreatic 
cancer preclinical models. The lead CCK-A isoform, selec-
tive antagonist PNB-028, bound to CCK-A at 12 nM with a 
60-fold selectivity towards CCK-A over CCK-B. Furthermore, 
it inhibited the proliferation of CCK-A-expressing colon and 
pancreatic cancer cells without affecting the proliferation of 
non-cancerous cells. PNB-028 was also extremely effective in 
inhibiting the growth of MAC-16 and LoVo colon cancer and 
MIA PaCa pancreatic cancer xenografts in immune-compro-
mised mice. Genome-wide microarray and kinase-array 
studies indicate that PNB-028 inhibited oncogenic kinases 
and angiogenic factors to inhibit the growth of colon cancer 
xenografts. Safety pharmacology and toxicology studies have 
indicated that PNB-028 is extremely safe and has a wide safety 
margin. These studies suggest that targeting CCK-A selectively 
renders promise to treat colon and pancreatic cancers and that 
PNB-028 could become the next-generation treatment option.
Introduction
Gastrointestinal cancers that include colon and pancreatic 
cancers account for over 140,000 new cancer cases and 
90,000 deaths each year in the USA (1). These cancers are the 
second and third leading causes of cancer-related deaths in the 
USA, respectively. Chemotherapy, radiotherapy, and surgery 
are the only choices available to treat colon and pancreatic 
cancers (2-4). Due to failure to diagnose at an early stage, the 
5-year survival rate of these cancer patients is much less than 
that of many other cancers (1,5). Colon and pancreatic cancers 
lack targeted therapeutics due to heterogeneity of the disease 
and diverse causative factors, including Helicobacter pylori 
(H. Pylori) bacteria (6,7), gut hormones such as gastrin and 
cholecystokinin (CCK) (8,9), and activation of cyclooxy-
genase (10,11) and NF-κB pathways (12).
The actions of two gut polypeptide hormones, gastrin and 
CCK, are mediated by G-protein coupled receptors (GPCRs), 
CCK-A and gastrin/CCK-B receptors. Since both gastrin and 
CCK share sequence homology, they bind to both CCK-A and 
CCK-B receptors (13). Gastrin, a peptide hormone secreted 
by the parietal cells of the stomach, binds to CCK receptor 
and elicits its function (14). Upon binding to CCK receptors, 
gastrin stimulates the release of histamine, which in turn 
releases hydrochloric acid/gastric acid. In addition, gastrin 
also plays important roles in cell proliferation and matura-
tion of the GI tract. Gastrin is also produced in excess in 
gastrinoma or gastric cancers (6,8). Blocking gastrin action 
by antagonizing CCK receptors will reduce gastric cancer 
incidence and growth.
Substantial evidence suggests that gastrin plays a pivotal 
role in stimulating colon cancer growth. It has been identified 
that gastrin plays an important role in Heliobacter-induced 
stomach cancer (15). More than 50% of the world population 
infected with Heliobacter results in gastric ulcers and stomach 
cancers. In addition, gastrin also plays an important role in 
stimulating the H. pylori-induced proliferation of gastric 
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cancer cells. Gastrin increases interleukin isoforms, IL-1β and 
IL-8 secretion, resulting in inflammatory process and subse-
quently cancer (16).
Notably, peptide CCK selectively binds to CCK-A, while 
gastrin binds with equal affinity to both CCk-A and CCk-B 
receptors (17). CCK-A is over 500-fold more selective towards 
CCK than gastrin, while CCK-B/gastrin receptor has equal 
affinity for both CCK and gastrin. This complicates the 
interpretation of the isoform that is responsible for the gastrin 
actions in colon cancer. While studies with clinical specimens 
clearly indicate higher expression of CCK-A in colon and 
pancreatic cancers, cell and tumor growth studies suggest 
a role for CCK-A and CCK-B in the proliferative effects of 
gastrin (13,18). One of the studies compared the antiprolif-
erative effects of non-isoform and isoform-selective CCK 
inhibitors in HT-29 colon cancer cells (18). While CCK-A 
isoform-selective inhibitors such as lorglumide and devazipide 
inhibited the proliferation of HT-29 cells, CCK-B-selective 
inhibitors such as PD-135158, L-365260 and non-isoform-
selective inhibitor such as proglumide had no effect on the 
proliferation of HT-29 cells. Collectively, tissue-expression 
and isoform-selective inhibitor studies suggest the importance 
of CCK-A in the proliferative effects of gastrin in colon cancer. 
Despite these studies, the role of CCK receptors in pancreatic 
cancer is unclear.
In the present study, we synthesized a library of highly 
potent isoform-selective CCK inhibitors and tested them in 
various preclinical models of colon and pancreatic cancers. 
The lead molecule PNB-028 (4-chloro-5-(fluorophenyl)-
5-hydroxy-1-isobutyl-1,5-dihydro-2H-pyrrol-2-one) bound 
potently and selectively to CCK-A at 12 nM with a 63-fold 
selectivity towards CCK-A. PNB-028 also inhibited CCK-A 
activity in a low nanomolar concentration. PNB-028 
inhibited the proliferation of CCK-A-expressing colon and 
pancreatic cancers cells without affecting the proliferation 
of non-cancerous cells. PNB-028 was also extremely effec-
tive in inhibiting the growth of MAC-16 and LoVo colon 
cancer and MIA PaCa pancreatic cancer xenografts in 
immune-compromised mice. Genome-wide microarray and 
kinase-array studies indicate a novel mechanism of action for 
PNB-028 in inhibiting the growth of colon cancer xenograft. 
Pharmacology and toxicology studies have indicated that 
PNB-028 is extremely safe and has a wide safety margin. 
These studies collectively suggest that selectively targeting 
CCK-A offers promise to treat colon and pancreatic cancers 
and that PNB-028 may become the next-generation treatment 
option.
Materials and methods
Reagents. CCK-A and CCK-B antibodies were procured from 
Abcam (Cambridge, MA, USA). Real-time PCR reagents 
and TaqMan primers and probes were obtained from Life 
Technologies (Carlsbad, CA, USA). Phospho-kinase array 
was purchased from R&D Systems (Minneapolis, MN, USA). 
Actin antibody was procured from Sigma (St. Louis, MO, 
USA). Matrigel was obtained from BD Biosciences. Cell 
culture reagents were purchased from Invitrogen and the 
American Type Culture Collection (ATCC; Manassas, VA, 
USA). All other reagents used were analytical grade.
Biological evaluation: [125]I-CCK-8 receptor binding assay. 
CCK-A and CCK-B receptor binding assays were performed 
with guinea pig cerebral cortex (CCKB) and rat pancreas 
(CCK-A). Male guinea pig brain tissues were prepared 
according to the method described by Saita et al (19). 
Pancreatic membranes were prepared as recommended by 
Charpentier et al (20).
Functional CCK assays. The CCK inhibitor lorglumide and 
PNB-028 were tested in triplicate with sulphated CCK8S as 
agonist and increasing concentrations of the ligand using a 
standardized 96-well plate discovery kit from DiscoverRx.
Anti-depression test: Forced swim test. Depression test animal 
protocols were approved by The Aston University Animal 
Care and Use Research Committee. The forced swim test was 
carried out in a glass cylinder filled with water at a tempera-
ture of ~25-28˚C. rats were gently placed into the water and 
the immobility time was recorded for 5 min. Immobility 
was defined as the absence of all movement with rats remain 
floating passively in water with their heads just above the 
water surface.
Colon and pancreatic cancer xenograft. All xenograft animal 
protocols were approved by The University of Tennessee 
Animal Care and Use Research Committee. MAC-16 and 
MIA PaCa cells were harvested, counted under microscope 
using trypan blue exclusion and a suspension in growth 
medium was prepared. LoVo cells were prepared as 1:1 
suspension of cells in medium and Matrigel. The cell suspen-
sion (5 million cells/mouse) was implanted subcutaneously 
in NSG mice. Once the tumors reached 100-200 mm3, the 
animals were randomized within the respective cell line and 
treated orally at 50 mg/kg/day. PNB-028 was dissolved in 
20% DMSO+80% PEG-300 and administered by oral gavage. 
Body weight and tumor volumes were measured thrice weekly. 
Animals were sacrificed (6 h after the last dose) when tumors 
reached 1,500 mm3 or when the animals lost over 20% body 
weight. Tumors were excised, weighed, and stored for further 
analysis (two parts snap-frozen and stored at -80˚C and one 
part stored in formalin for histology). Blood was collected, 
serum separated, and frozen at -80˚C for future analysis.
Cell culture. Colon cancer cells (HT29, Lovo, CaCo2, 
HCT116, SW480 and SW48) and non-cancerous HEK-293 
and COS-1 cells were obtained from ATCC. MAC-16 colon 
cancer cell line was a kind gift from dr jeff Molkentin 
(Cincinnati Children's hospital) and dr Michael j. tisdale 
(Aston University, Birmingham, UK). All cells, except LoVo, 
were grown in dulbecco's modified Eagle's medium (dMEM) 
supplemented with 10% fetal bovine serum (FBS). LoVo cells 
were grown in DMEM:F12 supplemented with 10% FBS.
RNA isolation, microarray analysis and gene expression. 
RNA was isolated from MAC-16 tumors (n=3/group) using 
Qiagen rneasy kit. rnA was quantified using nanodrop and 
diluted to equal concentrations of 100 ng/µl. RNA quality was 
determined using Agilent Bioanalyzer and RNA samples with 
rnA integrity number (rIn) >7 were used for microarray 
experiments (ST 2.0 mouse array from Affymetrix). Results 
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from microarray studies were analyzed using Affymetrix 
software [Transcriptome Analysis Console (TAC)]. Pathways 
differentially regulated by PNB-028 were identified using 
Ingenuity Pathway Analysis software.
Human phospho-kinase array. Protein extracts (500 µg/sample) 
that were prepared from MAC-16 tumors (n=4/group) were incu-
bated with protein kinase array membranes (R&D Systems) 
and the experiment was conducted according to the manufac-
turer's protocol. the blots were developed and quantified using 
Imagej software and the data were analyzed for statistical 
significance using jMP Pro 11 software.
Growth assay. Cells were plated at 4,000 cells/well of a 96-well 
plate in growth medium and treated with a dose response of 
PNB-028 (1 pM to 10 µM). After 3 days of treatment, cells 
were stained with sulfrhodamine blue reagent and the optical 
density, a measure of viable cells, was measured at 535 nm.
Western blotting. Cells were grown as described above. 
Protein extracts from cells or tumors were prepared and equal 
amount was run on a 4-20% SDS-PAGE, transferred to a nylon 
membrane, and western blotted for CCK-A and CCK-B using 
respective antibodies. Western blotting with actin antibody 
was performed as the loading control.
Metabolic stability of PNB028 with rat, dog, and human liver 
microsomes. PNB-028 was incubated with rat, dog, and human 
liver microsomes for two different time points and disap-
pearance of test compound was monitored by LC-MS/MS. 
Briefly, test and reference compounds were incubated with rat, 
dog or human liver microsomes (100 µl reaction; final drug 
concentration 1 µM, final dMSo concentration 0.05%, n=2). 
Incubation was carried out at 37˚C. for 0 min control (100% 
drug control), after adding the drug, reaction was terminated 
immediately with 100 µl of acetonitrile containing internal 
standard (tolbutamide, 500 ng/ml). Separate reactions were set 
up for 5 and 30 min at 37˚C and reactions were stopped by 
addition of acetonitrile. Contents were mixed well, and centri-
fuged at 13,200 rpm (Eppendorf 5810R) for 5 min. Supernatant 
fraction was collected and subjected to LC-MS/MS analysis. 
Reference compounds of reported/historical metabolic 
stability data such as verapamil (high clearance) and atenolol 
(low clearance) were included in the assay as positive controls.
Metabolic stability was determined as % parent compound 
remaining (% PCR) using the following formula:
 (peak area ratio of analysis to internal standard at 30 min) % PCR = -----------------------------------------------------------------------------------------------    x 100
 (peak area ratio of analysis to internal standard
 for 0 min control)
Analytical methods. Analysis of samples by LC-MS/MS 
was carried out using Sciex API 4000 system operated 
with Nexera™ UHPLC (Shimadzu) as front-end. Samples 
were separated on a Phenomenex Synergi Polar RP column 
(75x2.0 mm, 4 µm) using a gradient mode at a flow rate of 
1 ml/min. The mobile phase consisted of 0.1% formic acid in 
Milli-Q water (A) and 0.1% formic acid in acetonitrile (B). 
MS instrument was operated in positive mode. The multiple 
reactions monitoring transition of PNB028 was 283.9/210.8 
(Q1/Q3) with a de-clustering potential of 40 V, entrance poten-
tial 10 V and collision energy of 20 V. The curtain gas (5 V), 
ion-spray voltage (5,500 V), temperature (500˚C), nebulizer 
gas (GS1), and auxiliary gas (GS2) were set at 45 and 55 psi, 
respectively, and the interface heater was on.
Toxicology and safety pharmacology studies. Toxicology and 
safety pharmacology studies were performed in accordance 
with the ICh guidelines in Vimta Labs (hyderabad, India). 
the studies were performed in a GLP certified laboratory.
Statistical analysis. Data were statistically analyzed using 
jMP Pro 11 software. Experiments with only two groups were 
analyzed by t-test and experiments with more than two groups 
were analyzed by one way ANOVA.
Results
PNB-028 is a CCK-A-selective antagonist. PNB-028 (Fig. 1A) 
was selected from a library of structurally-related molecules 
Figure 1. PNB-028 is an isoform-selective CCK receptor antagonist. 
(A) Structure of PNB-028. (B) CCK-A and CCK-B binding assay. CCK-A 
(from rat pancreas) or CCK-B (from pig cerebral cortex) was incubated with 
radioactive CCK peptide alone or in combination with a dose response of 
PNB-028. Radioactivity, a measure of CCK displacement from the receptor 
binding pocket, was measured, analyzed and represented as IC50 value for 
PNB-028. (C) PNB-028 inhibits CCK-A effectively. Effect of PNB-028 on 
the CCK-A activity was evaluated using a standardized kit from DiscoverRx. 
Proglumide was used as a control. All experiments were performed in tripli-
cate and values are expressed as mean ± SE. CCK, cholecystokinin.
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based on structure-activity relationship studies. PNB-028 was 
tested in CCK-A and CCK-B competitive receptor binding 
assay study using rat pancreas and pig cerebral cortex. As 
shown in Fig. 1B, PNB-028 bound to CCK-A at 12 nM, 
but to CCK-B only at 750 nM, demonstrating over 60-fold 
selectivity for CCK-A. CCK-A and CCK-B functional assays 
demonstrated that PNB-028 effectively inhibited the CCK-A 
activity with IC50 value comparable to its binding efficacy 
of 12 nM (Fig. 1C), whereas, proglumide inhibited CCK-A 
activity with IC50 value >1,000 nM. these studies indicate that 
PNB-028 is a highly potent CCK-A-selective antagonist.
PNB-028 inhibits proliferation of colon and pancreatic cancer 
cell lines. Effect of PNB-028 on the proliferation of various 
colon (AGS and MAC13) and pancreatic (MIA PaCa and 
PANC) cancer cell lines was evaluated. PNB-028 effectively 
inhibited the proliferation of these cell lines with IC50 values in 
the range of 100-1,000 nM (Fig. 2A), whereas, devazipide and 
lorglumide inhibited growth of these cells only at concentra-
tions >1,000 and 10,000 nM.
The antiproliferative studies were expanded to additional 
colon cancer cell lines. Expression of CCK-A and CCK-B in 
colon cancer cell lines was determined by western blotting. In 
concordance with clinical specimens (13), colon cancer cell 
lines used in these experiments expressed CCK-A (Fig. 2B). 
Although four out of seven cell lines tested positive for CCK-B, 
CCK-B expression was weaker than that of CCK-A, indicating 
that CCK-A is the abundant isoform expressed in colon cancer.
Colon cancer cells were incubated with PNB-028 for 3 days 
and SRB assay was performed. PNB-028 effectively inhibited 
growth of MAC-16 chemoresistant murine colon cancer cells, 
SW-48, SW-480 and Lovo (Fig. 2C), while it had no effect 
on other colon cancer cell lines (HCT-116, HT-28 and CaCo2) 
and non-cancerous cell lines (HEK-293 and COS-1). Although 
all colon cancer cell lines expressed CCK-A, it is unclear why 
PNB-028 inhibited only four cell lines, but not the others.
Figure 2. PNB-028 inhibits colon and pancreatic cancer cell proliferation. (A) Cells shown in A were incubated with a dose response of PNB-028, lorglumide 
and devazepide for 3 days and cell number was measured by WSt assay. Values are expressed as IC50 value. (B) Expression of CCK-A and CCK-B was evalu-
ated in the indicated colon cancer cells by western blotting. Western blotting for actin was performed as loading control. (C) Colon cancer and non-cancerous 
cells (HEK-293 and COS-1) were incubated with PNB-028 for 3 days and the number of cells was measured by SRB assay. All experiments were performed 
in triplicates and the values are expressed as mean ± SE.
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Drug metabolism and pharmacokinetic (DMPK) properties 
of PNB-028. We evaluated the effect of PNB-028 on various 
dMPk properties. It is essential for a drug to possess ideal 
DMPK properties, to advance to in vivo studies and preclinical 
development. PNB-028 was extremely stable in human (HLM), 
rat (rLM), and dog (dLM) liver microsomes (table IA). Liver 
microsome studies indicated that after 30 min still 99% of 
PNB-028 in HLM, 43% in RLM and 55% of PNB-028 in 
DLM remained unmetabolized by respective liver micro-
somes (table IA). the data suggest species differences in 
metabolism with PNB-028 being more stable in HLM than 
RLM and DLM.
To evaluate the stability of PNB-028 in vivo, pharma-
cokinetic (PK) studies were performed in rats. PNB-028 
was administered intravenously (1 mg/kg b.wt.) and orally 
(20 mg/kg b.wt.) to rats and blood samples were collected 
at various time points until 24 h. PNB-028 concentration in 
plasma was measured using appropriate LC-MS/MS method. 
PNB-028 had a half-life of ~2.5 h with 100% bioavail-
ability (table IB). the Pk result suggests that despite a 
modest half-life in rat liver microsomes, PNB-028 possesses 
100% bioavailability. Considering that PNB-028 is more 
stable in HLM, we expect it to have longer half-life in the 
clinic.
Inhibiting drug metabolizing cytochrome (CyP) P-450 
enzymes will result in detrimental effects when patients 
consume more than one drug. CYP inhibition studies were 
conducted with PNB-028. PNB-028 at 10 µM did not inhibit 
major CYP enzymes, while the positive control inhibited the 
CyP enzymes significantly (table IC).
These results indicate that PNB-028 has favorable DMPK 
properties and has the potential to advance to in vivo studies.
PNB-028 inhibits colon and pancreatic cancer xenografts 
in NOD SCID γ (NSG) mice. To test the in vivo efficacy of 
PNB-028, colon and pancreatic cancer xenograft studies were 
performed. Cancer cells were implanted subcutaneously in 
NSG mice and when tumor volume reached 100-200 mm3, 
the animals were randomized and treated with vehicle or 
50 mg/kg/day PNB-028 orally. Tumor volume was measured 
thrice weekly and animals were sacrificed when tumors 
reached >1,500 mm3. Vehicle-treated MAC-16 tumors grew 
~2,000% in three weeks (Fig. 3A, left panel). MAC-16 is a 
murine chemoresistant colon tumor that aggressively grew 
to the extent of causing cachexia in mice. PNB-028 was 
extremely effective in slowing down the tumor growth signifi-
cantly providing a tumor growth inhibition (tGI) of ~75%. 
Tumor growth was completely arrested by PNB-028 for the 
first two weeks of treatment initiation even before showing 
signs of growth. Consistent with the tumor volume results, 
weight of PNB-028-treated tumors were 60-70% lower than 
the vehicle-treated tumors (Fig. 3A, right panel).
Based on in vitro proliferation studies shown in Fig. 2C, 
LoVo colon cancer cells were chosen as second xenograft 
model (Fig. 3B). LoVo tumors grew slower than MAC-16 
tumors and took almost 3 weeks to grow 600% (Fig. 3B, left 
panel). Growth of LoVo tumors was also significantly reduced 
by PnB-028. tumors weighed at sacrifice demonstrated an 
~50% lower weight in PNB-028-treated animals (Fig. 3B, 
right panel).
We tested the efficacy of PNB-028 on the growth of a 
pancreatic cancer xenograft (Fig. 3C). Cell proliferation studies 
shown in Fig. 2A indicate that PNB-028 effectively inhibited 
MIA PaCa pancreatic cancer cell proliferation with IC50 value 
around 150 nM. While vehicle-treated MIA PaCa pancreatic 
cancer cells implanted subcutaneously grew robustly, PNB-028-
treated tumors grew at a slower rate with ~60% tGI (fig. 3C, 
left panel). Tumor weights were inhibited by 50% by PNB-028 
compared to tumors from vehicle-treated animals.
table I. dMPk properties of PnB-028.
A, Stability of PNB-028 in rat (RLM), dog (DLM) and human 
(HLM) liver microsomes
 Mean % parent remaining after 30 min
 -------------------------------------------------------------------------------
Compound HLM RLM DLM
Verapamil 7.49 2.49 1.42
Atenolol 96.97 106.64 107.77
PNB208 99.66 42.73 55.26
B, The pharmacokinetic (PK) properties of PNB-028 
evaluated in rats
Parameters PO 20 mpk
AUC (0-t) (h*ng/ml) 1136.51±76.86
AuC (0-∞) (h*ng/ml) 1151.78±72.52
Cmax (ng/ml) 527.81±101-19
Tmax (h) 0.38±0.18
T1/2 (h) 2.28±1.31
% F 111.32±6.74
C, The effect of PNB-028 on cytochrome p450 (CYP) 
enzymes. 
 % Inhibition
 ----------------------------------------------------------------------------------------
Compound CYP2C9 CYP2D6 CYP3A4
Ref. 90.3 95.8 98
PNB-028 5.4 12.1 8.8
PNB-028 possesses optimum drug metabolism and pharmacoki-
netic (DMPK) properties. A, Stability of PNB-028 in rat (RLM), 
dog (DLM) and human (HLM) liver microsomes was evaluated by 
incubating the drug in vitro for 30 or 60 min and the percent drug 
remaining was measured by LC-MS/MS method. B, Pharmacokinetic 
(PK) properties of PNB-028 were evaluated in rats. Rats were admin-
istered with a single dose of 1 mg/kg PNB-028 intravenously and 
20 mg/kg PNB-028 orally. Blood was drawn at various time points 
and the availability of PNB-028 in serum was measured. C, Effect of 
PNB-028 on cytochrome p450 (CYP) enzymes was measured. Major 
CYP enzymes, CYP2D6, CYP3A4 and CYP2C9 were incubated 
with PNB-028 and the effect on enzyme activity was measured. Liver 
microsome and CYP inhibition studies were performed in triplicates, 
while the PK study was conducted with n=3 rats.
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PNB-028 inhibits oncogenic kinases in MAC-16 tumor xeno-
grafts. GPCR membrane receptors elicit their physiological 
effects through second messengers and kinases (21). To under-
stand PNB-028's mechanism of action, various molecular 
studies were performed. Protein extracted from MAC-16 xeno-
graft tumors (n=4/group) were subjected to phospho-kinase 
array to determine the effect of PNB-028 on kinase activity. 
table II contains the list of kinases significantly altered by 
PNB-028 in MAC-16 tumors. Except for p53 and STAT3, all 
other kinases shown in table II were inhibited significantly 
by PNB-028 compared to vehicle-treated controls. Several 
important oncogenic kinases, including src, yes, fAk and jnk 
were significantly inhibited by PnB-028. these results suggest 
that PNB-028 blocks oncogenic signaling pathways required 
by CCK-A to promote growth of colon and pancreatic cancers.
PNB-028 modulates expression of genes involved in cancer. 
To determine the effect of PNB-028 on gene expression, 
microarray studies were conducted with RNA isolated from 
vehicle- or PNB-028-treated MAC-16 tumors (n=3/group). 
PnB-028 significantly regulated over 1,400 genes compared 
to vehicle-treated samples (data not shown) with ~450 genes 
upregulated and 1,100 genes downregulated by 1.5-fold or 
greater. The list also contains 42 differentially regulated 
miRNAs, with 20 of them upregulated and 22 downregulated. 
Some of the microRNAs required for colon cancer growth 
(miR-34a, miR-194, miR-301b and miR-192) were differen-
tially regulated by PNB-028 (22-24).
Ingenuity pathway analysis identified cAMP signaling 
as the top canonical pathway overrepresented in the data 
set (table III). As expected cancer is the top disease repre-
sented in the data set with 476 genes belonging to cancer 
were differentially regulated by PNB-028. Various genes 
involved in cancer progression such as mug1, FLG2, CDHRS, 
wnt16 and others were the top ranked genes regulated by 
PNB-028 (25-27).
figure 3. PnB-028 effectively inhibits colon and pancreatic cancer xenografts. Colon cancer [MAC-16 (A) and Lovo (B)] and pancreatic cancer (MIA PaCa) (C) 
cells were implanted subcutaneously on the flanks of nSG mice. once the tumors reached 100-200 mm3, the animals were randomized and treated with vehicle 
or PnB-028 (50 mg/kg/day p.o.). tumor volume was measured thrice weekly. tumor weights were recorded at sacrifice (right panel) and tumors were stored 
at -80˚C for further analysis. Values are expressed as mean ± SE. *p<0.05, statistical significance.
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PNB-028 reduces depression and anxiety. Depression and 
anxiety are serious cancer-associated symptoms (28). CCK 
peptides alter neurological functions to promote depression 
and anxiety (29). CCK inhibitors have been demonstrated to 
alleviate depression and this property combined with anti-
oncogenic potential will provide additional benefits. We tested 
PNB-028 in a rat model of depression (Fig. 4). PNB-028 at 
0.5 and 5 mg/kg significantly reduced depression compared to 
saline-treated animals and the efficacy was comparable to the 
positive control desipramine.
PNB-028 is safe and well tolerated. As PNB-028 exhibited 
excellent efficacy in colon and pancreatic cancer xenografts, it 
table II. the kinases activated by PnB-028 in MAC-16 xenografts.
 Vehicle PNB-028
 --------------------------------------------------------------- ----------------------------------------------------------------
Kinase Avg SE Avg SE P-value
Ref. 1 0 1 0
jnk1/2/3 0.308248 0.01989 0.09294 0.010537 0.0016
EGFR 0.241026 0.027824 0.105439 0.01653 0.022
MSK1/2 0.542699 0.040771 0.311258 0.012877 0.009
p53 0.025831 0.003003 0.039743 0.002691 0.013
HSP27 0.185137 0.013716 0.055009 0.005738 0.008
Src 0.274963 0.027102 0.092557 0.006062 0.00236
Yes 0.382946 0.032932 0.14205 0.010512 0.0019
STAT3 0.027749 0.005336 0.040122 0.003246 0.0426
Chk-2 0.371529 0.02679 0.143098 0.013097 0.00134
FAK 0.281422 0.021302 0.098282 0.015685 0.00195
PDGF Rb 0.205851 0.019172 0.065606 0.014887 0.00374
PRAS40 0.541283 0.035194 0.23595 0.010209 0.00098
PnB-028 significantly inhibits kinase activity. Effect of PnB-028 on kinase phosphorylation was evaluated by incubating protein extracts 
obtained from vehicle- or PNB-028-treated MAC-16 tumors (n=4) from the xenograft study on phosphor-kinase array. Arrays were processed 
according to the manufacturer's protocol. only kinases that are significantly regulated by PnB-028 are expressed in the present study.
Figure 4. PNB-028 alleviates depression. PNB-028 (0.5 or 5 mg/kg) or 
desipramine was administered to rats (n=5) and their effect on depression 
was evaluated using the forced-swim test.
table III. Microarray ingenuity pathway analysis.
A, Top canonical pathways
Top canonical pathway P-value
cAMP signaling 1.32e-4
Transcriptional regulatory network 8.06e-4
GPCR signaling 5.54e-3
B, Molecular and cellular functions
Molecular and cellular functions No. molecules
Cell signaling 27
Nucleic acid metabolism 22
Cell death and survival 29
C, Disease
Diseases No. molecules
Cancer 476
Organismal injury 480
Neurological disease 90
PNB-028 alters expression of genes. RNA was extracted from 
vehicle- or PNB-028-treated MAC-16 xenograft tumors (n=3) and 
were subjected to microarray analysis (mouse ST2.0 array). Pathways 
significantly altered by PnB-028 were identified using ingenuity 
pathway analysis software and represented as A, top canonical path-
ways; B, molecular and cellular functions; and C, disease.
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was advanced to toxicology and safety pharmacology studies 
conducted in accordance with ICh guidelines. PnB-028 tested 
for up to 28 days exhibited impeccable safety with no adverse 
events (table IV). PnB-028 at doses as high as 400 mg/kg 
was safe. Genotoxic studies also demonstrated lack of effects.
Collectively these studies demonstrate that PNB-028 has 
the potential to become the next-generation colon and pancre-
atic cancer targeting therapeutic.
Discussion
In the present study we showed, using preclinical models, that 
a novel and safe CCK-A-selective antagonist can effectively 
treat colon and pancreatic cancers in preclinical models. 
Although other CCK inhibitors have been used in the past 
to treat gastrointestinal ulcers (proglumide, devazepide and 
lorglumide), pain in combination with opioids (proglumide), 
anorexia (devazepide), and irritable bowel syndrome (lorglu-
mide), PnB-028 is the first to show activity on both colon and 
pancreatic cancers and on depression (30-32). Development 
of other CCK antagonists L-365,260, L-369,293, YF-476, 
RP-69758, LY-288,513 and PD-145,942 was halted due to poor 
oral bioavailability (33). Even the PK properties of widely used 
CCK antagonist proglumide is not optimum. PNB-028 may be 
the first in the CCk antagonist class to have high oral bioavail-
ability in preclinical species and have significantly better 
stability in human liver microsomes. PNB-028 possesses all 
desirable drug-like properties to advance to clinic. Although 
previous clinical trial with a CCK antagonist, MK-329, in 
pancreatic cancer patients failed to provide benefit, PnB-028 
may offer a breakthrough for gastrointestinal cancers that have 
no targeted therapeutics (2).
PNB-028 effectively inhibited growth of MAC-16 
chemoresistant aggressively growing murine colon cancer 
allograft (Fig. 3A) (34). This suggests that inhibiting CCK-A 
may benefit patients relapsed from chemotherapy. Similarly, 
PNB-028 slowed the growth of another colon cancer cell line 
xenograft (Fig. 3B) and a pancreatic cancer xenograft (Fig. 3C). 
These growth inhibition results were obtained without affecting 
body weight of animals or inhibiting growth of normal cell 
lines (Fig. 2C). Gross pathological observation of MAC-16 
tumors indicated that while vehicle-treated tumors were highly 
vascular, PnB-028-treated tumors were not vascular. In order 
to understand the effect of PNB-028 on angiogenic factors, 
microarray data was probed for growth factors that promote 
angiogenesis. Fibroblast growth factor (FGF)-2 and -4 were 
inhibited significantly by PNB-028. Literature evidences 
suggest that FGF is a highly potent angiogenic growth factor 
with FGF-2 being more potent than even vascular endothelial 
growth factor (VEGF) (35). Another important growth factor 
responsible for angiogenesis and cancer cell proliferation, 
fGf-4, was also significantly inhibited by PnB-028 (36).
table IV. toxicology and safety pharmacology results.
Study Species Dose (mg/kg/day p.o.) Adverse effect
28 days toxicology Rat 50,100,200 No adverse effects or mortality
Motor coordination safety Rat 50,80 No difference from vehicle in latency of fall in roto-rod
pharmacology   motor coordination experiment
Gastrointestinal safety Rat 50,80 No change in charcoal intestinal transit study
pharmacology
7 days DRF Rat 100,200,400 No treatment-related adverse events or mortality
14 days DRF Dog 50,200 No treatment-related adverse events of mortality
Ames test Bacteria 39-5,000 (µg/plate) Negative response at all concentrations
i.v. acute toxicology Mice 15,30,60 2 males and 2 females died at 60 mg/kg dose
   15 and 30 mg/kg did not have any adverse events
28 day toxicology Rat 50, 100 No adverse effects of mortality
Chromosomal aberration Rat 200, 1,000 No chromosomal aberration
toxicology and safety pharmacology studies with PnB-028 were performed in accordance with ICh guidelines in GLP-accredited facility.
Figure 5. Model depicting actions of PNB-028.
ONCOLOGY REPORTS  35:  2097-2106,  2016 2105
PNB-028 selectively inhibited kinases and cell signaling 
pathways that are responsible for cancer cell prolif-
eration (table II). Pathway analysis of the kinase-array data 
indicated that PNB-028 inhibits integrin- and EGF-signaling 
pathways. Both integrin and EGFR pathways activate 
src-FAK association resulting in activation of RAC, PAK, 
jnk, MSk 1 and 2, resulting in increased proliferation and 
survival (Fig. 5) (37). Activation of FAK and src by integrin 
and EGFR family results in increased proliferation, migra-
tion and cell survival. While most of these oncogenic kinases 
were activated, phosphorylation of tumor suppressor protein 
p53 was increased by PNB-028. This suggests that although 
the predominant mechanism for anti-tumorigenic effect of 
PNB-028 is to inhibit proliferative signals, it also positively 
affect tumor suppressors to provide additive effects.
Unlike many oncogenic targets, CCK is a pleotropic 
therapeutic target that promotes the development of multiple 
diseases. Many of these diseases, including pain, depression, 
and anxiety, could be considered cancer-associated diseases. 
Inhibiting CCk will not only reduce the growth of colon and 
pancreatic cancers, but will also alleviate depression, anxiety 
and pain. On the contrary inhibiting therapeutic targets such 
as estrogen receptor α (ER-α) will reduce breast cancer cell 
proliferation, while promoting osteoporosis and hot flashes. 
This demonstrates that the pleotropic role is unique to only 
certain therapeutic targets such as CCK, while others have 
opposing role in different tissues.
References
  1. Siegel r, Ma j, Zou Z and jemal A: Cancer Statistics, 2014. CA 
Cancer j Clin 64: 9-29, 2014.
  2. Abbruzzese jL: new applications of gemcitabine and future 
directions in the management of pancreatic cancer. Cancer 95 
(Suppl 4): S941-S945, 2002.
  3. Macdonald jS: Clinical overview: Adjuvant therapy of gastro-
intestinal cancer. Cancer Chemother Pharmacol 54 (Suppl 1): 
S4-S11, 2004.
  4. okusaka t, Ishii h, funakoshi A, ueno h, furuse j and 
Sumii t: A phase I/II study of combination chemotherapy with 
gemcitabine and 5-fluorouracil for advanced pancreatic cancer. 
jpn j Clin oncol 36: 557-563, 2006.
  5. Dal Maso L, Guzzinati S, Buzzoni C, Capocaccia R, Serraino D, 
Caldarella A, Dei Tos AP, Falcini F, Autelitano M, Masanotti G, 
et al: Long-term survival, prevalence, and cure of cancer: A 
population-based estimation for 818 902 Italian patients and 26 
cancer types. Ann Oncol 25: 2251-2260, 2014.
  6. Aly A, Shulkes A and Baldwin GS: Gastrins, cholecystokinins 
and gastrointestinal cancer. Biochim Biophys Acta 1704: 1-10, 
2004.
  7. Shmuely h, Melzer E, Braverman M, domnitz n and yahav j: 
Helicobacter pylori infection is associated with advanced 
colorectal neoplasia. Scand j Gastroenterol 49: 516-517, 2014.
  8. jin G, Westphalen CB, hayakawa y, Worthley dL, Asfaha S, 
Yang X, Chen X, Si Y, Wang H, Tailor Y, et al: Progastrin stimulates 
colonic cell proliferation via CCK2R- and β-arrestin-dependent 
suppression of BMP2. Gastroenterology 145: 820-30.e10, 2013.
  9. Smith jP and Solomon tE: Cholecystokinin and pancreatic 
cancer: the chicken or the egg? Am j Physiol Gastrointest Liver 
Physiol 306: G91-G101, 2014.
10. Larsson k and jakobsson Pj: Inhibition of microsomal prosta-
glandin E synthase-1 as targeted therapy in cancer treatment. 
Prostaglandins Other Lipid Mediat 120: 161-165, 2015.
11. Walia S, Kamal R, Kanwar SS and Dhawan DK: Cyclooxygenase 
as a target in chemoprevention by probiotics during 1,2-dimethyl-
hydrazine induced colon carcinogenesis in rats. Nutr Cancer 67: 
603-611, 2015.
12. Wang S, Liu Z, Wang L and Zhang X: nf-kappaB signaling 
pathway, inf lammation and colorectal cancer. Cell Mol 
Immunol 6: 327-334, 2009.
13. Clerc P, Dufresne M, Saillan C, Chastre E, André T, Escrieut C, 
Kennedy K, Vaysse N, Gespach C and Fourmy D: Differential 
expression of the CCK-A and CCK-B/gastrin receptor genes 
in human cancers of the esophagus, stomach and colon. Int j 
Cancer 72: 931-936, 1997.
14. rehfeld jf, friis-hansen L, Goetze jP and hansen tV: the 
biology of cholecystokinin and gastrin peptides. Curr Top Med 
Chem 7: 1154-1165, 2007.
15. takaishi S, tu S, dubeykovskaya ZA, Whary Mt, Muthupalani S, 
rickman Bh, rogers AB, Lertkowit n, Varro A, fox jG, et al: 
Gastrin is an essential cofactor for helicobacter-associated 
gastric corpus carcinogenesis in C57BL/6 mice. Am j Pathol 175: 
365-375, 2009.
16. konturek PC, konturek Sj, Bielanski W, karczewska E, 
Pierzchalski P, Duda A, Starzynska T, Marlicz K, Popiela T, 
Hartwich A, et al: Role of gastrin in gastric cancerogenesis in 
Helicobacter pylori infected humans. j Physiol Pharmacol 50: 
857-873, 1999.
17. Silvente-Poirot S, Dufresne M, Vaysse N and Fourmy D: The 
peripheral cholecystokinin receptors. Eur j Biochem 215: 
513-529, 1993.
18. González-Puga C, García-navarro A, Escames G, León j, 
López-Cantarero M, Ros E and Acuña-Castroviejo D: Selective 
CCK-A but not CCK-B receptor antagonists inhibit HT-29 
cell proliferation: Synergism with pharmacological levels of 
melatonin. j Pineal res 39: 243-250, 2005.
19. Saita Y, Yazawa H, Honma Y, Nishida A, Miyata K and Honda K: 
Characterization of yM022: Its CCkB/gastrin receptor binding 
profile and antagonism to CCk-8-induced Ca2+ mobilization. Eur 
j Pharmacol 269: 249-254, 1994.
20. Charpentier B, Pelaprat D, Durieux C, Dor A, Reibaud M, 
Blanchard jC and roques BP: Cyclic cholecystokinin analogues 
with high selectivity for central receptors. Proc Natl Acad Sci 
USA 85: 1968-1972, 1988.
21. Tuteja N: Signaling through G protein coupled receptors. Plant 
Signal Behav 4: 942-947, 2009.
22. Aherne St, Madden Sf, hughes dj, Pardini B, naccarati A, 
Levy M, Vodicka P, Neary P, Dowling P and Clynes M: 
Circulating miRNAs miR-34a and miR-150 associated with 
colorectal cancer progression. BMC Cancer 15: 329, 2015.
23. Sundaram P, hultine S, Smith LM, dews M, fox jL, Biyashev d, 
Schelter jM, huang Q, Cleary MA, Volpert oV, et al: p53-respon-
sive miR-194 inhibits thrombospondin-1 and promotes 
angiogenesis in colon cancers. Cancer Res 71: 7490-7501, 2011.
24. Wang yX, Zhang Xy, Zhang Bf, yang CQ, Chen XM and 
Gao hj: Initial study of micrornA expression profiles of colonic 
cancer without lymph node metastasis. j dig dis 11: 50-54, 2010.
25. henderson Cj, ritchie kj, McLaren A, Chakravarty P and 
Wolf Cr: Increased skin papilloma formation in mice lacking 
glutathione transferase GSTP. Cancer Res 71: 7048-7060, 2011.
26. yin y, Betsuyaku t, Garbow jr, Miao j, Govindan r and 
ornitz dM: rapid induction of lung adenocarcinoma by fibro-
blast growth factor 9 signaling through FGF receptor 3. Cancer 
Res 73: 5730-5741, 2013.
27. Qian D, Chen K, Deng H, Rao H, Huang H, Liao Y, Sun X, Lu S, 
yuan Z, Xie d, et al: MicroRNA-374b suppresses proliferation 
and promotes apoptosis in T-cell lymphoblastic lymphoma by 
repressing AKT1 and Wnt-16. Clin Cancer Res 21: 4881-4891, 
2015.
28. Gold M, dunn LB, Phoenix B, Paul SM, hamolsky d, Levine jd 
and Miaskowski C: Co-occurrence of anxiety and depressive 
symptoms following breast cancer surgery and its impact on 
quality of life. Eur j oncol nurs: jul 15, 2015 (Epub ahead of print). 
pii: S1462-3889(15)30003-X. doi: 10.1016/j.ejon.2015.06.003. 
29. del Boca C, Lutz PE, Le Merrer j, koebel P and kieffer BL: 
Cholecystokinin knock-down in the basolateral amygdala 
has anxiolytic and antidepressant-like effects in mice. 
Neuroscience 218: 185-195, 2012.
30. Tariq M, Parmar NS and Ageel AM: Gastric and duodenal 
antiulcer and cytoprotective effects of proglumide in rats. j 
Pharmacol Exp Ther 241: 602-607, 1987.
31. hirst Bh, Elliott kj, ryder h and Szelke M: Inhibition of gastrin- 
and histamine-stimulated gastric acid secretion by gastrin and 
cholecystokinin antagonists in the rat. Aliment Pharmacol 
Ther 5: 31-39, 1991.
32. Herranz R: Cholecystokinin antagonists: Pharmacological and 
therapeutic potential. Med Res Rev 23: 559-605, 2003.
33. kalindjian SB and Mcdonald IM: Strategies for the design of 
non-peptide CCK2 receptor agonist and antagonist ligand. Curr 
Top Med Chem 7: 1195-1204, 2007.
PONNUSAMY et al:  CCk-A SELECtIVE InhIBItor for CoLon And PAnCrEAtIC CAnCErS2106
34. Bibby MC, double jA, Ali SA, fearon kC, Brennan rA and 
tisdale Mj: Characterization of a transplantable adenocarcinoma 
of the mouse colon producing cachexia in recipient animals. j 
natl Cancer Inst 78: 539-546, 1987.
35. Cao r, Bråkenhielm E, Pawliuk r, Wariaro d, Post Mj, 
Wahlberg E, Leboulch P and Cao Y: Angiogenic synergism, 
vascular stability and improvement of hind-limb ischemia by 
a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613, 
2003.
36. delli Bovi P, Curatola AM, kern fG, Greco A, Ittmann M and 
Basilico C: An oncogene isolated by transfection of Kaposi's 
sarcoma DNA encodes a growth factor that is a member of the 
FGF family. Cell 50: 729-737, 1987.
37. teoh CM, tam jk and tran t: Integrin and GPCr crosstalk 
in the regulation of ASM contraction signaling in Asthma. j 
Allergy 2012: 341282, 2012.
